|
Amendment to ASX announcement - Zelira's diabetic nerve pai
|
8 June 2023 at 10:10am
|
|
Initial Director's Interest Notice
|
1 June 2023 at 3:55pm
|
|
Final Director's Interest Notice
|
1 June 2023 at 3:55pm
|
|
Proposed issue of securities - ZLD
|
31 May 2023 at 4:45pm
|
|
Zelira Non-Executive Director Appointed
|
31 May 2023 at 4:35pm
|
|
Top Line Results Investor Presentation
|
31 May 2023 at 12:10pm
|
|
Investor Webinar - Top line trial results
|
31 May 2023 at 11:05am
|
|
Zeliras diabetic nerve pain drug outperforms Lyrica
|
31 May 2023 at 10:50am
|
|
Trading Halt
|
29 May 2023 at 9:35am
|
|
ZLD secures additional US$3.25M investment in HOPE SPV
|
22 May 2023 at 8:45am
|
|
Appendix 4C Cash Flow Report
|
27 April 2023 at 12:30pm
|
|
March 2023 Quarterly Activities Report
|
27 April 2023 at 12:30pm
|
|
Section 708A Cleansing Notice
|
21 March 2023 at 7:50pm
|
|
Application for quotation of securities - ZLD
|
21 March 2023 at 7:50pm
|
|
Proposed issue of securities - ZLD
|
15 March 2023 at 10:00am
|
|
Zelira raises A$1.77 million from US-based investors
|
15 March 2023 at 10:00am
|
|
Trading Halt
|
13 March 2023 at 9:35am
|
|
Appendix 4D & FY23 Interim Financial Report
|
28 February 2023 at 2:25pm
|
|
Zelira HOPE 1 SPV Investor Presentation
|
22 February 2023 at 1:35pm
|
|
Initial Director's Interest Notice
|
21 February 2023 at 8:35pm
|
|
Zelira HOPE 1 SPV Investor Briefing Webinar
|
21 February 2023 at 10:00am
|
|
Zelira Executive Director Appointed
|
20 February 2023 at 1:05pm
|
|
Trading Halt
|
17 February 2023 at 9:55am
|
|
ZLD secures US$8.6 million funding for HOPE 1 US FDA trials
|
15 February 2023 at 10:05am
|
|
Trading Halt
|
13 February 2023 at 9:55am
|
|
Appendix 4C Cash Flow Report
|
31 January 2023 at 9:00am
|
|
December 2022 Quarterly Activities Report
|
31 January 2023 at 8:55am
|
|
Zelira receives $1.14 million cash R&D Tax Incentive
|
30 January 2023 at 2:15pm
|
|
Receipt of Creso Shares and Settlement of Health House loan
|
10 January 2023 at 2:40pm
|
|
Partial Receipt and variation of Health House loan
|
21 November 2022 at 9:55am
|
|
HHI: Scheme implementation deed executed
|
21 November 2022 at 9:55am
|
|
ZLD Completes Enrolment for Diabetic Nerve Pain Drug Trial
|
21 November 2022 at 9:05am
|
|
New Constitution
|
17 November 2022 at 6:45pm
|
|
Results of Meeting
|
17 November 2022 at 4:25pm
|
|
2022 Annual General Meeting Presentation
|
17 November 2022 at 11:00am
|
|
Zelira Retail Investor Presentation
|
14 November 2022 at 8:40am
|
|
Sydney Retail Investor Briefing Time Change
|
11 November 2022 at 3:45pm
|
|
Zelira Retail Investor Briefing Details
|
4 November 2022 at 9:05am
|
|
Appendix 4C Cash Flow Report
|
31 October 2022 at 9:10am
|
|
September 2022 Quarterly Activities Report
|
31 October 2022 at 9:10am
|
|
Notice of Annual General Meeting/Proxy Form
|
14 October 2022 at 2:10pm
|
|
Letter to Shareholders
|
14 October 2022 at 2:00pm
|
|
Notification of cessation of securities - ZLD
|
30 September 2022 at 2:25pm
|
|
Diabetic Nerve Pain Drug Trial Summary Update
|
21 September 2022 at 4:59pm
|
|
AGM Date and Closing Date for Director Nominations
|
21 September 2022 at 1:45pm
|
|
Annual Report to shareholders
|
16 September 2022 at 10:55am
|
|
ZLDs Diabetic Nerve Pain Drug Trial Two-Thirds Enrolled
|
15 September 2022 at 8:55am
|
|
Partial Receipt of Health House Loan
|
8 September 2022 at 9:45am
|
|
Investor Briefing Webinar Presentation
|
7 September 2022 at 10:15am
|
|
Investor Briefing Webinar Details
|
6 September 2022 at 8:45am
|
Zelira Therapeutics